1. De-intensification of postoperative radiotherapy in head and neck cancer irrespective of human papillomavirus status—results of a prospective multicenter phase II trial (DIREKHT Trial)
- Author
-
Marlen Haderlein, Jens von der Grün, Panagiotis Balermpas, Claus Rödel, Matthias G. Hautmann, Felix Steger, Christopher Bohr, Thomas Hehr, Carmen Stromberger, Volker Budach, Markus Schymalla, Rita Engenhart-Cabillic, Lukas Kocik, Hans Geinitz, Ursula Nestle, Gunter Klautke, Claudia Scherl, Christine Gall, Benjamin Frey, Philipp Schubert, Sabine Semrau, Oliver Ott, Marco Kesting, Heinrich Iro, Sarina K. Mueller, and Rainer Fietkau
- Subjects
head and neck cancer ,radiotherapy ,HPV ,de-intensification ,postoperative ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundCurrent standard treatment concepts in head and neck squamous cell carcinoma (HNSCC) are based on former studies using 2D and 3D treatment plans. However, modern radiation techniques allow for a more precise and individual dose application. Therefore, in a clearly defined patient population, de-intensified risk-adapted radiation is investigated.MethodsPatients with newly diagnosed HNSCC after surgery (with resection margins ≥1 mm and cM0) with the following tumor stages (TNM 7th Edition) were eligible for the study: oral cavity, oropharynx, or larynx: pT1–3, pN0–pN2b; hypopharynx: pT1–2, pN1. The patients should have either a low risk of local recurrence [≤pT2, resection margin ≥5 mm, no peritumoral lymphangiosis (L0), and no perineural invasion] or contralateral lymph node metastasis (≤3 ipsilateral lymph node metastases, in case of well-lateralized oropharyngeal or oral cavity cancer contralateral cN0, otherwise pN0). Patients were assigned to three different treatment regimes with reduction of the treated volume, radiation dose, or both, according to tumor stage and results of surgery performed. The primary objective was to show an LRR of
- Published
- 2024
- Full Text
- View/download PDF